69 research outputs found
Resolution of Linear Algebra for the Discrete Logarithm Problem Using GPU and Multi-core Architectures
In cryptanalysis, solving the discrete logarithm problem (DLP) is key to
assessing the security of many public-key cryptosystems. The index-calculus
methods, that attack the DLP in multiplicative subgroups of finite fields,
require solving large sparse systems of linear equations modulo large primes.
This article deals with how we can run this computation on GPU- and
multi-core-based clusters, featuring InfiniBand networking. More specifically,
we present the sparse linear algebra algorithms that are proposed in the
literature, in particular the block Wiedemann algorithm. We discuss the
parallelization of the central matrix--vector product operation from both
algorithmic and practical points of view, and illustrate how our approach has
contributed to the recent record-sized DLP computation in GF().Comment: Euro-Par 2014 Parallel Processing, Aug 2014, Porto, Portugal.
\<http://europar2014.dcc.fc.up.pt/\>
Advancing urban transitions and transformations research
Urban transitions and transformations research fosters a dialogue between sustainability transitions theory an inter- and transdisciplinary research on urban change. As a field, urban transitions and transformations research encompasses plural analytical and conceptual perspectives. In doing so, this field opens up sustainability transitions research to new communities of practice in urban environments, including mayors, transnational municipal networks, and international organizations
Technical Design Report for the: PANDA Micro Vertex Detector
This document illustrates the technical layout and the expected performance
of the Micro Vertex Detector (MVD) of the PANDA experiment. The MVD will detect
charged particles as close as possible to the interaction zone. Design criteria
and the optimisation process as well as the technical solutions chosen are
discussed and the results of this process are subjected to extensive Monte
Carlo physics studies. The route towards realisation of the detector is
outlined.Comment: 189 pages, 225 figures, 41 table
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years
Monitoring and behavior of unsaturated volcanic pyroclastic in the Metropolitan Area of San Salvador, El Salvador
How can irrigated agriculture adapt to climate change? Insights from the Guadiana Basin in Spain
Towards Climate Change Adaptation Strategies in the Baltic Sea Region - Developing Policies and Adaptation Strategies to Climate Change in the Baltic Sea Region
Der Tunel Assay bestätigt den durch Methadon induzierten Zelltod in Glioblastomzelllinien und normalen Astrozyten
�ber den Acetalphosphatidgehalt des Serums gesunder Personen und seine Beziehung zu anderen Lipoiden
Can you see it? Retinal vessel analysis (RVA) for cerebral vasospasm - A prospective pilot study
- …